Clinical Trial Detail

NCT ID NCT04013880
Title ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

ASTX727 + Olutasidenib

Age Groups: senior adult

Additional content available in CKB BOOST